Study of Safety and Efficacy of Probiotic LGG for Gastrointestinal Cancers

Share this content:
Researchers are investigating the effectiveness of LGG in reducing the incidence of acute toxicity among patients with gastrointestinal cancers receiving chemoradiation.
Researchers are investigating the effectiveness of LGG in reducing the incidence of acute toxicity among patients with gastrointestinal cancers receiving chemoradiation.

Title: A Phase I and Randomized Controlled Phase II Trial of the Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer1

Principal Investigator: Mathew Ciorba, MD, Washington University School of Medicine

Description: For this randomized phase 1/2 study (ClinicalTrials.gov Identifier: NCT01790035), researchers are investigating the effectiveness of probiotic Lactobacillus rhamnosus GG (LGG) in reducing the incidence of acute toxicity among patients with gastrointestinal cancers receiving chemoradiation.

One-hundred and twenty patients will be randomly assigned to receive oral LGG (1010 viable bacteria) twice daily or placebo at baseline at least 3 days before initiation until 2 weeks following radiotherapy. Patients who opt not to receive LGG will not undergo randomization and will receive standard of care radiotherapy; the first 20 patients will serve as a non-intervention comparator cohort.

The primary outcome of the study is to assess the safety, tolerability, and efficacy of LGG among patients receiving abdominal or pelvic chemoradiation with a fluoropyrimidine-based regimen.

Estimated study enrollment is 120 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01790035.

Status: Open and recruiting patients as of January 16, 2018.

This study is sponsored by the Washington University School of Medicine.

Reference

  1. ClinicalTrials.gov. Probiotic LGG for prevention of side effects in patients undergoing chemoradiation for gastrointestinal cancer (LGG). NCT01790035. https://clinicaltrials.gov/ct2/show/NCT01790035. Accessed January 16, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs